CGON
CG Oncology, Inc.
Price Chart
Latest Quote
$61.08
+0.65 (+1.08%)
Current Price
| Previous Close | $60.43 |
| Open | $63.70 |
| Day High | $63.70 |
| Day Low | $60.01 |
| Volume | 1,799,782 |
Stock Information
| Shares Outstanding | 88.20M |
| Total Debt | $7.58M |
| Cash Equivalents | $1.08B |
| Revenue | $5.07M |
| Net Income | $-186.74M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.39B |
| EPS (TTM) | $-2.34 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.25B |
| Sales | $5.07M |
| Income | $-186.74M |
| Book/sh | $12.40 |
| Cash/sh | $12.20 |
| Employees | 142 |
Financial Ratios
| Quick Ratio | 30.60 |
| Current Ratio | 31.30 |
| Debt/Eq | 0.69 |
Returns & Margins
| ROA | -14.42% |
| ROE | -20.79% |
| Operating Margin | -6130.10% |
Ownership
| Insider Ownership | 0.23% |
| Institutional Ownership | 110.05% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -21.98 |
| P/S | 1062.40 |
| P/B | 4.92 |
Analyst Data
| Recommendation | none |
| Target Price | $90.29 |
Technical Indicators
| SMA20 | $58.90 |
| SMA50 | $64.44 |
| SMA200 | $51.87 |
| RSI | 47.35 |
| ATR | 3.0284 |
| Shares Float | 65.82M |
| Short Float | 11.32% |
| Short Ratio | 10.60 |
| Volatility | 0.31 |
| Rel Volume | 2.28 |
Performance History
| Week | +5.97% |
| Month | -3.51% |
| Quarter | -7.26% |
| 6 Months | +61.37% |
| YTD | +46.16% |
| Year | +132.77% |
| 10 Years | +64.33% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $61.08 | 2,259,000 |
| 2026-06-17 | $60.43 | 873,600 |
| 2026-06-16 | $60.28 | 530,800 |
| 2026-06-15 | $59.55 | 962,100 |
| 2026-06-12 | $59.56 | 933,800 |
| 2026-06-11 | $57.64 | 783,200 |
| 2026-06-10 | $54.92 | 824,200 |
| 2026-06-09 | $56.67 | 1,236,700 |
| 2026-06-08 | $54.40 | 828,300 |
| 2026-06-05 | $53.72 | 967,300 |
| 2026-06-04 | $56.09 | 653,900 |
| 2026-06-03 | $54.42 | 982,200 |
| 2026-06-02 | $55.53 | 1,164,700 |
| 2026-06-01 | $59.23 | 814,500 |
| 2026-05-29 | $62.29 | 1,225,900 |
| 2026-05-28 | $60.73 | 689,000 |
| 2026-05-27 | $60.80 | 1,029,000 |
| 2026-05-26 | $61.89 | 1,701,600 |
| 2026-05-22 | $64.25 | 652,800 |
| 2026-05-21 | $64.59 | 685,300 |
| 2026-05-20 | $64.76 | 784,500 |
| 2026-05-19 | $63.30 | 675,100 |
About CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
đ° Latest News
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
MarketBeat âĸ 2026-06-10T07:02:30Z
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
MarketBeat âĸ 2026-06-07T21:05:47Z
Did CG Oncologyâs Leadership Consolidation Around CEO Kuan Just Shift CGONâs Commercialization Narrative?
Simply Wall St. âĸ 2026-05-31T21:08:52Z
Sector Update: Healthcare Stocks Decline Late Afternoon
MT Newswires âĸ 2026-05-26T19:54:37ZSector Update: Healthcare Stocks Decline Tuesday Afternoon
MT Newswires âĸ 2026-05-26T17:50:29ZCG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
MarketBeat âĸ 2026-05-21T02:04:44Z
Assessing CG Oncology (CGON) Valuation After Positive Phase 2 CORE-008 Bladder Cancer Data
Simply Wall St. âĸ 2026-05-17T14:11:27Z
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
MarketBeat âĸ 2026-05-15T07:07:54Z
RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst
Insider Monkey âĸ 2026-05-10T23:14:32Z
What CG Oncology (CGON)'s Bigger Loss and Cash Runway Through 2029 Means For Shareholders
Simply Wall St. âĸ 2026-05-10T06:06:16Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $4,647,000 | $0 | $0 | - |
| Cost Of Revenue | $4,647,000 | $0 | $0 | - |
| Total Revenue | $4,040,000 | $1,139,000 | $204,000 | $191,000 |
| Operating Revenue | $4,040,000 | $1,139,000 | $204,000 | $191,000 |
| Expenses | ||||
| Total Expenses | $194,814,000 | $115,805,000 | $55,653,000 | $35,437,000 |
| Other Income Expense | $-152,000 | $3,000 | $-62,000 | $-196,000 |
| Other Non Operating Income Expenses | $-152,000 | $3,000 | $-62,000 | $-196,000 |
| Net Non Operating Interest Income Expense | $29,931,000 | $26,624,000 | $6,904,000 | $-1,000 |
| Operating Expense | $190,167,000 | $115,805,000 | $55,653,000 | $35,437,000 |
| General And Administrative Expense | $73,526,000 | $33,703,000 | $9,901,000 | $6,408,000 |
| Total Other Finance Cost | - | - | $-6,904,000 | $1,000 |
| Interest Expense | - | - | - | $1,000 |
| Interest Expense Non Operating | - | - | - | $1,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-160,995,000 | $-88,039,000 | $-48,607,000 | $-35,443,000 |
| Net Interest Income | $29,931,000 | $26,624,000 | $6,904,000 | $-1,000 |
| Interest Income | $29,931,000 | $26,624,000 | $6,904,000 | - |
| Normalized Income | $-160,995,000 | $-88,039,000 | $-48,607,000 | $-35,443,000 |
| Net Income From Continuing And Discontinued Operation | $-160,995,000 | $-88,039,000 | $-48,607,000 | $-35,443,000 |
| Total Operating Income As Reported | $-190,774,000 | $-114,666,000 | $-55,449,000 | $-35,246,000 |
| Net Income Common Stockholders | $-160,995,000 | $-88,039,000 | $-67,798,000 | $-43,788,000 |
| Net Income | $-160,995,000 | $-88,039,000 | $-48,607,000 | $-35,443,000 |
| Net Income Including Noncontrolling Interests | $-160,995,000 | $-88,039,000 | $-48,607,000 | $-35,443,000 |
| Net Income Continuous Operations | $-160,995,000 | $-88,039,000 | $-48,607,000 | $-35,443,000 |
| Pretax Income | $-160,995,000 | $-88,039,000 | $-48,607,000 | $-35,443,000 |
| Interest Income Non Operating | $29,931,000 | $26,624,000 | $6,904,000 | - |
| Operating Income | $-190,774,000 | $-114,666,000 | $-55,449,000 | $-35,246,000 |
| Gross Profit | $-607,000 | $1,139,000 | $204,000 | - |
| Per Share | ||||
| Diluted EPS | $-2.08 | $-1.41 | $-15.65 | $-11.71 |
| Basic EPS | $-2.08 | $-1.41 | $-15.65 | $-11.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-189,329,000 | $-114,634,000 | $-55,432,000 | $-35,231,000 |
| Reconciled Depreciation | $1,445,000 | $32,000 | $17,000 | $15,000 |
| EBITDA (Bullshit earnings) | $-189,329,000 | $-114,634,000 | $-55,432,000 | $-35,231,000 |
| EBIT | $-190,774,000 | $-114,666,000 | $-55,449,000 | $-35,246,000 |
| Diluted Average Shares | $77,303,440 | $62,496,725 | $4,330,933 | $3,740,892 |
| Basic Average Shares | $77,303,440 | $62,496,725 | $4,330,933 | $3,740,892 |
| Diluted NI Availto Com Stockholders | $-160,995,000 | $-88,039,000 | $-67,798,000 | $-43,788,000 |
| Research And Development | $116,641,000 | $82,102,000 | $45,752,000 | $29,029,000 |
| Selling General And Administration | $73,526,000 | $33,703,000 | $9,901,000 | $6,408,000 |
| Other Gand A | $34,280,000 | $12,311,000 | $9,901,000 | $3,098,000 |
| Salaries And Wages | $39,246,000 | $21,392,000 | $5,542,000 | $3,310,000 |
| Preferred Stock Dividends | - | - | $19,191,000 | $8,345,000 |
Fetched: 2026-06-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $741,730,000 | $733,377,000 | $184,790,000 | $125,177,000 |
| Total Assets | $791,592,000 | $754,797,000 | $199,301,000 | $147,747,000 |
| Total Non Current Assets | $32,117,000 | $587,000 | $5,177,000 | $539,000 |
| Other Non Current Assets | $1,678,000 | $94,000 | $19,000 | $33,000 |
| Goodwill And Other Intangible Assets | $10,872,000 | $0 | - | - |
| Other Intangible Assets | $575,000 | - | - | - |
| Current Assets | $759,475,000 | $754,210,000 | $194,124,000 | $147,208,000 |
| Other Current Assets | $15,067,000 | $12,212,000 | $6,358,000 | $3,424,000 |
| Inventory | $1,565,000 | $0 | - | - |
| Receivables | $688,000 | $0 | $92,000 | $303,000 |
| Accounts Receivable | $688,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $742,155,000 | $741,998,000 | $187,674,000 | $143,481,000 |
| Cash And Cash Equivalents | $32,490,000 | $257,068,000 | $8,266,000 | $88,143,000 |
| Non Current Deferred Assets | - | $0 | $4,667,000 | $0 |
| Other Receivables | - | $781,000 | $92,000 | $303,000 |
| Debt | ||||
| Total Debt | $7,021,000 | $238,000 | $461,000 | $15,944,000 |
| Long Term Debt And Capital Lease Obligation | $6,106,000 | $52,000 | $244,000 | $6,789,000 |
| Long Term Debt | $3,000,000 | - | - | $6,532,000 |
| Current Debt And Capital Lease Obligation | $915,000 | $186,000 | $217,000 | $9,155,000 |
| Current Debt | - | - | - | $8,966,000 |
| Other Current Borrowings | - | - | - | $8,966,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $38,990,000 | $21,420,000 | $14,511,000 | $22,570,000 |
| Total Non Current Liabilities Net Minority Interest | $8,154,000 | $52,000 | $257,000 | $7,141,000 |
| Other Non Current Liabilities | $1,741,000 | - | $13,000 | $352,000 |
| Non Current Deferred Liabilities | $307,000 | $0 | - | - |
| Non Current Deferred Taxes Liabilities | $307,000 | $0 | - | - |
| Current Liabilities | $30,836,000 | $21,368,000 | $14,254,000 | $15,429,000 |
| Other Current Liabilities | $802,000 | $436,000 | $451,000 | $173,000 |
| Current Deferred Liabilities | $286,000 | $0 | $1,017,000 | $0 |
| Payables And Accrued Expenses | $20,617,000 | $14,953,000 | $9,747,000 | $4,268,000 |
| Payables | $5,714,000 | $6,517,000 | $3,242,000 | $985,000 |
| Accounts Payable | $5,714,000 | $6,517,000 | $3,242,000 | $985,000 |
| Equity | ||||
| Common Stock Equity | $752,602,000 | $733,377,000 | $-123,100,000 | $-77,693,000 |
| Total Equity Gross Minority Interest | $752,602,000 | $733,377,000 | $184,790,000 | $125,177,000 |
| Stockholders Equity | $752,602,000 | $733,377,000 | $184,790,000 | $125,177,000 |
| Retained Earnings | $-378,976,000 | $-217,981,000 | $-129,942,000 | $-81,335,000 |
| Preferred Stock Equity | - | - | $307,890,000 | $202,870,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $202,870,000 |
| Other | ||||
| Ordinary Shares Number | $80,689,128 | $76,154,783 | $63,482,511 | $63,482,511 |
| Share Issued | $80,689,128 | $76,154,783 | $63,482,511 | $63,482,511 |
| Tangible Book Value | $741,730,000 | $733,377,000 | $-123,100,000 | $-77,693,000 |
| Invested Capital | $755,602,000 | $733,377,000 | $-123,100,000 | $-62,195,000 |
| Working Capital | $728,639,000 | $732,842,000 | $179,870,000 | $131,779,000 |
| Capital Lease Obligations | $4,021,000 | $238,000 | $461,000 | $446,000 |
| Total Capitalization | $755,602,000 | $733,377,000 | $184,790,000 | $131,709,000 |
| Additional Paid In Capital | $1,131,570,000 | $951,350,000 | $6,842,000 | $3,642,000 |
| Capital Stock | $8,000 | $8,000 | $307,890,000 | $202,870,000 |
| Common Stock | $8,000 | $8,000 | $0 | $0 |
| Long Term Capital Lease Obligation | $3,106,000 | $52,000 | $244,000 | $257,000 |
| Current Deferred Revenue | $286,000 | $0 | - | - |
| Current Capital Lease Obligation | $915,000 | $186,000 | $217,000 | $189,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $8,216,000 | $5,793,000 | $2,822,000 | $1,833,000 |
| Current Accrued Expenses | $14,903,000 | $8,436,000 | $6,505,000 | $3,283,000 |
| Goodwill | $10,297,000 | $0 | - | - |
| Net PPE | $19,567,000 | $493,000 | $491,000 | $506,000 |
| Accumulated Depreciation | $-1,474,000 | $-87,000 | - | - |
| Gross PPE | $21,041,000 | $580,000 | $491,000 | $506,000 |
| Leases | $10,499,000 | $0 | - | - |
| Other Properties | $9,953,000 | $221,000 | $491,000 | $506,000 |
| Machinery Furniture Equipment | $589,000 | $359,000 | - | - |
| Properties | $0 | $0 | - | - |
| Other Short Term Investments | $709,665,000 | $484,930,000 | $179,408,000 | $55,338,000 |
| Preferred Stock | - | $0 | $307,890,000 | $202,870,000 |
Fetched: 2026-06-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-132,480,000 | $-78,947,000 | $-45,679,000 | $-29,818,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-132,346,000 | $-78,713,000 | $-45,679,000 | $-29,804,000 |
| Cash Flow From Continuing Operating Activities | $-132,346,000 | $-78,713,000 | $-45,679,000 | $-29,804,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-134,000 | $-234,000 | - | $-14,000 |
| Investing Cash Flow | $-245,822,000 | $-300,764,000 | $-121,195,000 | $-55,352,000 |
| Cash Flow From Continuing Investing Activities | $-245,822,000 | $-300,764,000 | $-121,195,000 | $-55,352,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $147,450,000 | $629,469,000 | $104,627,000 | $119,526,000 |
| Financing Cash Flow | $153,590,000 | $628,279,000 | $86,997,000 | $119,692,000 |
| Cash Flow From Continuing Financing Activities | $153,590,000 | $628,279,000 | $86,997,000 | $119,692,000 |
| Net Other Financing Charges | $-316,000 | $-3,424,000 | $-3,421,000 | - |
| Net Preferred Stock Issuance | $0 | $0 | $104,627,000 | $119,526,000 |
| Preferred Stock Issuance | $0 | $0 | $104,627,000 | $119,526,000 |
| Net Common Stock Issuance | $147,450,000 | $629,469,000 | $0 | $166,000 |
| Common Stock Issuance | $147,450,000 | $629,469,000 | $0 | $166,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-365,000 | $-16,291,000 | $0 |
| Interest Paid Supplemental Data | $103,000 | $0 | $376,000 | $1,091,000 |
| Income Tax Paid Supplemental Data | $16,000 | $0 | $0 | $0 |
| End Cash Position | $32,490,000 | $257,068,000 | $8,266,000 | $88,143,000 |
| Beginning Cash Position | $257,068,000 | $8,266,000 | $88,143,000 | $53,607,000 |
| Changes In Cash | $-224,578,000 | $248,802,000 | $-79,877,000 | $34,536,000 |
| Proceeds From Stock Option Exercised | $6,456,000 | $2,599,000 | $2,082,000 | $166,000 |
| Net Issuance Payments Of Debt | $0 | $-365,000 | $-16,291,000 | $0 |
| Net Long Term Debt Issuance | $0 | $-365,000 | $-16,291,000 | $0 |
| Long Term Debt Payments | $0 | $-365,000 | $-16,291,000 | $0 |
| Net Investment Purchase And Sale | $-223,721,000 | $-300,530,000 | $-121,195,000 | $-55,338,000 |
| Sale Of Investment | $844,139,000 | $745,412,000 | $396,416,000 | $0 |
| Purchase Of Investment | $-1,067,860,000 | $-1,045,942,000 | $-517,611,000 | $-55,338,000 |
| Net Business Purchase And Sale | $-21,967,000 | $0 | $0 | - |
| Purchase Of Business | $-21,967,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-134,000 | $-234,000 | $0 | $-14,000 |
| Purchase Of PPE | $-134,000 | $-234,000 | $0 | $-14,000 |
| Change In Working Capital | $2,276,000 | $2,906,000 | $3,439,000 | $4,439,000 |
| Change In Other Current Liabilities | $-487,000 | $0 | $0 | - |
| Change In Other Current Assets | $-1,584,000 | $-75,000 | $13,000 | $52,000 |
| Change In Payables And Accrued Expense | $7,011,000 | $8,743,000 | $6,149,000 | $3,314,000 |
| Change In Accrued Expense | $8,655,000 | $5,468,000 | $4,137,000 | $3,332,000 |
| Change In Payable | $-1,644,000 | $3,275,000 | $2,012,000 | $-18,000 |
| Change In Account Payable | $-1,644,000 | $3,275,000 | $2,012,000 | $-18,000 |
| Change In Prepaid Assets | $-1,900,000 | $-5,762,000 | $-2,723,000 | $1,073,000 |
| Change In Inventory | $-444,000 | $0 | $0 | - |
| Change In Receivables | $-320,000 | $0 | $0 | - |
| Changes In Account Receivables | $-320,000 | $0 | $0 | - |
| Other Non Cash Items | $-734,000 | $-22,000 | $819,000 | $509,000 |
| Stock Based Compensation | $26,676,000 | $11,402,000 | $1,528,000 | $676,000 |
| Unrealized Gain Loss On Investment Securities | $-1,014,000 | $-4,992,000 | $-2,875,000 | $0 |
| Amortization Of Securities | $-1,014,000 | $-4,992,000 | $-2,875,000 | $0 |
| Depreciation Amortization Depletion | $1,445,000 | $32,000 | $17,000 | $15,000 |
| Depreciation And Amortization | $1,445,000 | $32,000 | $17,000 | $15,000 |
| Net Income From Continuing Operations | $-160,995,000 | $-88,039,000 | $-48,607,000 | $-35,443,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-13